VMD-928
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
What will happen during the trial?
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 242 patients (estimated)
- Tags
- Tyrosine Kinase (TK) Inhibitor
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 1401
- NCT Identifier
- NCT03556228
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.